The MarketWatch News Section was not involved in the generation of this content.
New York, New York, Jan 20, 2021 (Newsfile Corp by means of COMTEX) —
New York, New York–(Newsfile Corp. – January 20, 2021) – Pomerantz LLP is investigating statements on behalf of buyers of Ocugen, Inc.(“Ocugen” or the “Corporation”) (NASDAQ: OCGN). These buyers are suggested to get in touch with Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.
The investigation problems no matter whether Ocugen and certain of its officers and/or directors have engaged in securities fraud or other unlawful enterprise methods.
On January 12, 2021, Ocugen issued a press launch asserting the cancelation of a Corporation stockholder conference earlier scheduled for January 13, 2021, the next day. The press release said that “[t]he Corporation strategies to reevaluate the details of” a proposed share improve “in light of the latest opportunity addition of COVAXIN™ to its pipeline as perfectly as its compliance with Nasdaq’s Listing Rule 5550(a)(2).”
On this information, Ocugen’s stock selling price fell $.26 for each share, or 10.44%, to close at $2.23 for every share on January 12, 2021.
The Pomerantz Agency, with offices in New York, Chicago, Los Angeles, and Paris is acknowledged as 1 of the premier firms in the spots of corporate, securities, and antitrust course litigation. Founded by the late Abraham L. Pomerantz, regarded as the dean of the class action bar, the Pomerantz Organization pioneered the area of securities class steps. These days, much more than 80 decades afterwards, the Pomerantz Agency carries on in the tradition he set up, preventing for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered a lot of multimillion-dollar damages awards on behalf of course associates. See www.pomerantzlaw.com.
Get hold of:
Robert S. Willoughby
888-476-6529 ext. 7980
To watch the source model of this press launch, remember to stop by https://www.newsfilecorp.com/launch/72504
copyright (c) newsfile corp. 2021. all legal rights reserved
The MarketWatch Information Office was not involved in the creation of this material.